Compare WHR & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WHR | ADMA |
|---|---|---|
| Founded | 1911 | 2004 |
| Country | United States | United States |
| Employees | 41000 | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 1994 | 2012 |
| Metric | WHR | ADMA |
|---|---|---|
| Price | $31.85 | $9.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $74.33 | $25.67 |
| AVG Volume (30 Days) | ★ 2.6M | 2.1M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.59% | N/A |
| EPS Growth | ★ 196.42 | N/A |
| EPS | N/A | ★ 0.35 |
| Revenue | ★ $21,253,000,000.00 | $42,219,783.00 |
| Revenue This Year | N/A | $27.46 |
| Revenue Next Year | $3.48 | $22.11 |
| P/E Ratio | ★ N/A | $27.20 |
| Revenue Growth | 2.58 | ★ 43.85 |
| 52 Week Low | $31.52 | $7.21 |
| 52 Week High | $94.82 | $20.46 |
| Indicator | WHR | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 32.89 | 50.95 |
| Support Level | N/A | $9.23 |
| Resistance Level | $45.07 | $9.49 |
| Average True Range (ATR) | 1.36 | 0.34 |
| MACD | -0.18 | 0.03 |
| Stochastic Oscillator | 5.80 | 66.54 |
Whirlpool Corp is a manufacturer and marketer of kitchen and laundry appliances, with its presence in different markets around the world. It offers products like refrigerators, washing machines, cooktops, ovens, freezers, and others, which are marketed through various brands such as KitchenAid, Maytag, Amana, Brastemp, Consul, Whirlpool, Jennair, etc. The company's operating and reportable segments are: Major Domestic Appliances (MDA) North America (its key revenue-generating segment), MDA Europe, MDA Latin America, and Small Domestic Appliances (SDA) Global.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.